An antibody–drug conjugate consisting of an anti-HER2 monoclonal antibody linked to the topoisomerase I inhibitor deruxtecan (DXd). It binds HER2-expressing tumor cells, is internalized, and releases DXd to induce DNA damage and apoptosis, with potential bystander effect.
Anti-HER2 monoclonal antibody linked to the topoisomerase I inhibitor deruxtecan (DXd). Binds HER2 on tumor cells, is internalized, and releases DXd to inhibit Top1, causing DNA damage, cell-cycle arrest, and apoptosis; also mediates ADCC and has a membrane-permeable payload enabling a bystander killing effect.
Binds HER2, is internalized, and releases the topoisomerase I inhibitor deruxtecan (DXd), causing Top1 inhibition, DNA damage, cell-cycle arrest, and apoptosis; Fc can also mediate ADCC. Membrane-permeable payload allows bystander killing.
An antibody–drug conjugate comprising an anti-TROP2 monoclonal antibody linked to SN-38 (the active metabolite of irinotecan). After binding TROP2 on tumor cells and internalization, it releases SN-38 to inhibit topoisomerase I, causing DNA damage and apoptosis, with possible bystander effect.
Anti-TROP2 monoclonal antibody linked to the topoisomerase I inhibitor SN-38. After binding TROP2 on tumor cells and internalization, the linker is cleaved to release SN-38, which inhibits topoisomerase I, causing DNA damage and apoptosis; the membrane-permeable payload can also produce a bystander effect.
The anti-TROP2 ADC binds TROP2, is internalized, and releases SN-38, which inhibits topoisomerase I, causing DNA damage and apoptosis (with possible bystander effect).
Anti-CD20 monoclonal antibody that depletes B cells; used as second-line or added to first-line therapy.
Anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, reducing autoantibody production and B-cell antigen presentation.
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity (CDC) and Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) by NK cells/macrophages; it can also induce apoptosis of CD20+ cells.
Humanized anti-HER2 IgG1 monoclonal antibody that binds domain IV of ERBB2, inhibits HER2 signaling, and mediates ADCC.
Humanized IgG1 monoclonal antibody targeting HER2/ERBB2 (binds domain IV) on tumor cells; inhibits HER2 signaling and downstream PI3K/AKT and MAPK pathways, reduces receptor activation, and mediates immune effector killing via antibody-dependent cellular cytotoxicity (ADCC).
Trastuzumab binds HER2 on tumor cells and its Fc engages Fcγ receptors on NK cells and other effectors to mediate antibody-dependent cellular cytotoxicity (ADCC), killing the coated cells.
Humanized anti-HER2 monoclonal antibody that binds domain II of ERBB2, blocking HER2 dimerization with HER3/EGFR and downstream signaling.
Humanized IgG1 monoclonal antibody targeting HER2 (ERBB2) domain II, preventing HER2 heterodimerization (especially with HER3/EGFR), thereby inhibiting downstream PI3K/AKT and MAPK signaling; can also mediate antibody-dependent cellular cytotoxicity, resulting in growth arrest and apoptosis of HER2-positive tumor cells.
Pertuzumab opsonizes HER2-expressing cells and engages FcγR-bearing immune effectors (e.g., NK cells) to mediate ADCC; HER2 dimerization blockade can also trigger apoptosis.